Abstract
G protein-coupled receptors (GPCRs) linked to stimulatory G (Gs) proteins (GsPCRs) mediate increases in intracellular cyclic AMP as consequence of activation of nine adenylyl cyclases , which differ considerably in their cellular distribution and activation mechanisms. Once produced, cyclic AMP may act via distinct intracellular signaling effectors such as protein kinase A and the exchange proteins activated by cAMP (Epacs). More recently, attention has been focused on the efflux of cAMP through a specific transport system named multidrug resistance proteins that belongs to the ATP-binding cassette transporter superfamily. Outside the cell, cAMP is metabolized into adenosine, which is able to activate four distinct subtypes of adenosine receptors, members of the GPCR family: A1, A2A, A2B, and A3. Taking into account that this phenomenon occurs in numerous cell types, as consequence of GsPCR activation and increment in intracellular cAMP levels, in this review, we will discuss the impact of cAMP efflux and the extracellular cAMP-adenosine pathway on the regulation of GsPCR-induced cell response.
Seven transmembrane receptors are able to transmit extracellular signals into the intracellular compartment via activation of heterotrimeric G proteins, which consist of the guanine nucleotide-binding Gα subunit and the dimeric βγ subunits (Pierce et al., 2002). These G protein-coupled receptors (GPCRs) are ubiquitously distributed and precisely regulate a myriad of intracellular processes upon agonist stimulation. GPCRs may also activate β-arrestin-dependent signaling, which functions as an adaptor protein that regulates GPCR signaling and trafficking, having the ability to activate intracellular pathways independently of G proteins (DeWire et al., 2007).
The membrane-associated G proteins can be divided into four families according to the primary sequence similarity of Gα subunits: Gαs (αs, αolf), Gαi (αi1–αi3, αt, αo1–αo2, αζ), Gαq/11 (αq, α11, α14–α16), Gα12 (α12, α13). The sequence homologies also define the Gα subunit coupling to downstream effector molecules, such as phospholipase C-β, adenylyl cyclase (AC), RhoGEFs and/or ion channels (Moreira, 2014).
Conformational changes of GPCR, induced by extracellular agonist binding, reduces the affinity of GDP to Gα subunit, resulting in sequential dissociation of GDP-Gα complex, interaction of GTP with Gα, and dissociation of heterotrimeric complex Gα–βγ into Gα subunit and βγ dimmer (Pierce et al., 2002). Focusing on activation of GPCRs linked to stimulatory G (Gs) proteins (GsPCR), the GTP-Gαs complex is able to interact and activate all available membrane bound AC isoforms (AC1–AC9), increasing the intracellular generation of adenosine 3′,5′-cyclic monophosphate (3′,5′-cAMP or cAMP). Conversely, by activating inhibitory G (Gi) protein, agonists of GiPCR elicit the selective inhibition of AC1, AC5, and AC6, reducing the intracellular cAMP content(Sadana and Dessauer, 2009).
Cyclic AMP was first described by Rall et al. (1957) who showed that sympathomimetic amines and glucagon were able to induce the synthesis of a heat-stable factor formed by particulate fractions of liver homogenates in the presence of ATP and Mg2+. Identified as adenine ribonucleotide, the compound was identical to the cAMP described by Cook et al. (1957) at the same year. Since then, intracellular signaling through cAMP has been described in virtually every cell (Antoni, 2012). The protein kinase A (PKA), a serine/threonine kinase ubiquitously expressed in mammal tissues, was the first cAMP downstream target to be identified (Walsh et al., 1968). Formed by two regulatory and two catalytic subunits, activation of PKA involves the cooperative binding of four cAMP molecules to two regulatory subunits, leading the catalytic subunits free to phosphorylate target proteins. Intracellular cAMP is also able to directly modulate ion channels (Bradley et al., 2005), such as the hyperpolarization-activated cyclic nucleotide-gated channels (HCN channels) expressed in the cardiac sinoatrial node (Larsson, 2010). Additionally, exchange proteins directly activated by cAMP (Epac) explained various effects of cAMP that could not be attributed to the PKA or cAMP-gated ion channels (Gloerich and Bos, 2010).
Phosphodiesterases, MRP/ABCC Transporters and cAMP Efflux
The fine regulation of intracellular cAMP signaling is made by phosphodiesterases (PDEs), enzymes that catalyze the hydrolysis of cAMP into AMP. Actually, the superfamily of PDE enzymes is comprised of 11 families, namely PDE1–PDE11. While PDE4, PDE7, and PDE8 are specific for cAMP, PDE5–PDE6, and PDE9 are specific for guanosine 3′,5′-cyclic monophosphate (cGMP) and PDE1–PDE3 and PDE10–PDE11 hydrolyze both cAMP and cGMP (Bender and Beavo, 2006; Francis et al., 2011). By hydrolyzing the cyclic nucleotide monophosphates, PDEs regulate several important physiological processes, such as vascular resistance, cardiac output, visceral motility, immune response, inflammation, neuroplasticity, vision, and reproduction (Azevedo et al., 2014). Therefore, altered expression of PDE or changes in the enzyme activity have been associated with a number of pathological conditions, including erectile dysfunction, pulmonary hypertension, acute refractory cardiac failure, chronic obstructive pulmonary disease and various types of cancer (Azevedo et al., 2014).
In addition to PDE, the intracellular concentration of cAMP is regulated by its efflux into the extracellular space through a specific transport system named multidrug resistance proteins (MRP; Cheepala et al., 2013) that belongs to the ATP-binding cassette (ABC) transporter superfamily (subfamily C). Three of them (MRP4/ABCC4, MRP5/ABCC5, and MRP8/ABCC11) have the ability to actively extrude cAMP and cGMP from the cell (Kruh and Belinsky, 2003) with different kinetic parameters (Km values in the μM range; Jedlitschky et al., 2000; Chen et al., 2001; Guo et al., 2003; Sager and Ravna, 2009).
The MRP-mediated cAMP efflux has been shown in many cell types, including rodent skeletal muscle (Godinho and Costa, 2003), human platelets (Jedlitschky et al., 2004) vascular smooth muscle cells (Sassi et al., 2008; Cheng et al., 2010), pulmonary arteries (Hara et al., 2011) and cardiac myocytes (Sassi et al., 2011). Therefore, it was proposed that by working synergistically with PDE enzymes, MRP-mediated cAMP efflux would preserve the cell from excessive levels of intracellular cAMP (Jedlitschky et al., 2000; Chen et al., 2001). Although reasonable, this premise was not consistent with the high energetic cost of pumping cAMP out of cell (Godinho and Costa, 2003; Chiavegatti et al., 2008). Thus, it was hypothesized that cAMP might also function as an extracellular signaling molecule (Jackson and Raghvendra, 2004). In fact, since the middle 1960s, extracellular effects of cAMP have been reported in different mammal tissues and organs. For example, intravenous infusion of cAMP is known to produce a wide range of responses, including increased adrenal corticosterone secretion in hypophysectomized rats (Imura et al., 1965), increment in heart rate, cardiac output, and blood glucose, reduction of blood pressure (Levine and Vogel, 1966) and increment in calcium and phosphate plasma concentration (Rasmussen et al., 1968). cAMP infusion effects seem to be exclusively extracellular since most cells are impermeable to cAMP (Robison et al., 1965).
Ecto-Phosphodiesterases, Ecto-Nucleotidases, and the Extracellular cAMP-Adenosine Pathway
The idea of an extracellular role for cAMP gained strength in the late 1990s when it was established that extracellular cAMP could be sequentially metabolized into AMP and adenosine, a phenomenon named “extracellular cAMP-adenosine pathway” (Mi and Jackson, 1998). Actually, the existence of ecto-enzymes with PDE activity was first demonstrated in frog skeletal muscle by Woo and Manery (1973), who showed extracellular generation of [14C]AMP as consequence of incubation of intact posterior leg muscles with [14C]cAMP. The degradation of cAMP was markedly inhibited by theophylline, suggesting the presence of cAMP-phosphodiesterase activity at the muscle fiber surface (Woo and Manery, 1973). Later, ecto-phosphodiesterase activity was found in rodent liver cells (Smoake et al., 1981), vascular smooth muscles (Dubey et al., 1996; Jackson et al., 1997), adipocytes (Strouch et al., 2005), skeletal muscle (Chiavegatti et al., 2008), rat ileum (Giron et al., 2008), astrocytes and microglia (Verrier et al., 2011) and many other cells.
In those cells, following the extracellular degradation of 3′,5′-cAMP by ecto-PDE, 5′-AMP is rapidly hydrolyzed to adenosine by membrane-bound ecto-5′-nucleotidases (EC 3.1.3.5), also known as CD73. The ecto-5′-nucleotidase is a 70-kDa cell surface glycoprotein found in most tissues that functions as the major enzymatic source of interstitial adenosine (Colgan et al., 2006). Although ecto-5′-nucleotidases also hydrolyzes other ribo- and deoxyribonucleoside 5′-monophosphates including cytidine-, uridine-, inosine-, and guanosine-5′-monophosphates, AMP is the most effectively hydrolyzed nucleotide (Zimmermann et al., 2012). Thus, by hydrolyzing 5′-AMP derived from either ATP or cAMP, ecto-5′-nucleotidases act as a limiting point for the extracellular provision of adenosine and, as consequence, for activation of adenosine receptors (ARs).
In addition to ecto-5′-nucleotidases, other three types of surface-located ecto-nucleotidases are involved in the extracellular nucleosides degradation and, consequently, in the extracellular adenosine formation: ecto-nucleoside triphosphate diphosphohydrolases (EC 3.6.1.5), ecto-nucleotide pyrophosphatase/PDEs (EC 3.6.1.9 and EC 3.1.4.1) and alkaline phosphatases (APs; EC 3.1.3.1). While ecto-5′-nucleotidases is nucleotide-specific, ecto-nucleotide pyrophosphatase/PDEs and ecto-nucleoside triphosphate diphosphohydrolases hydrolyze both ATP and ADP (Zimmermann et al., 2012).
Adenosine Receptors and the Extracellular cAMP-Adenosine Pathway
The extracellular degradation of cAMP allows the activation of membrane associated ARs by its metabolite adenosine. Pharmacologically, four distinct subtypes of ARs, members of the GPCR family, are described: A1, A2A, A2B, and A3 (Fredholm et al., 2011). These receptors have a very broad tissue distribution, performing relevant physiological effects in central nervous system (Ribeiro et al., 2002; Wei et al., 2011), cardiovascular (Headrick et al., 2013; Idzko et al., 2014a) and musculoskeletal systems (Burnstock et al., 2013) and many other tissues (Vallon et al., 2006; Sheth et al., 2014). Activation of adenosine is also involved in pathophysiological conditions such as cancer, inflammation (Antonioli et al., 2013; Idzko et al., 2014b) and neurodegenerative diseases, with potential therapeutic implications for Parkinson’s and Alzheimer’s diseases (Ribeiro et al., 2002).
AR subtypes exhibit different affinities for the endogenous agonist (Muller and Jacobson, 2011): A1, A2A, and A3 display high to moderate affinity (Ki = 100, 310, and 290 nM, respectively) to adenosine whereas A2B has low affinity (Ki = 15 μM). Furthermore, distinct signaling transduction pathways are mobilized by each AR, leading to diverse cellular effects. The A1 and A3 are preferentially coupled to the Gi/o family of G-proteins whereas the A2A and A2B couple to Gs proteins (Trincavelli et al., 2010). Thus, as shown in Figure 1, depending on the receptor subtypes expressed in the cell, the extracellular cAMP-adenosine pathway will be able to increase (Figure 1A) or attenuate (Figure 1B) the intracellular cAMP production, by activating or inhibiting ACs, via Gs and Gi proteins, respectively. Therefore, the final biological effect of the extracellular cAMP-adenosine pathway will depend on AR subtype expressed by the target cell and on the amount of cAMP pumped out of the cell.
FIGURE 1
In fact, the extracellular cAMP-adenosine signaling can be even more complex, as in addition to classical Gs and Gi pathways, AR subtypes can also activate Gq protein (A2B and A3), phospholipase C-β (A1, A2B, and A3), PKC (A2B and A3), KATP channel (A3), and ERK1/2 (A1, A2A/A2B, and A3) p38 (A1 and A2B) MAPK cascade (Feoktistov et al., 1999; Schulte and Fredholm, 2003), which in turn are able to modulate AC activation (Sadana and Dessauer, 2009).
Activation of GsPCR and the Extracellular cAMP-Adenosine Pathway
Taking into account that cAMP may function as an extracellular signaling molecule, it is possible to assume that, by stimulating AC enzymes, all GsPCRs may have significant impact on cAMP efflux and extracellular cAMP-adenosine signaling. Actually, by studying the contribution of cAMP efflux and the extracellular cAMP-adenosine pathway on skeletal muscle physiology, we showed that cAMP egress induced by activation of GsPCR, such as β-adrenoceptors and calcitonin gene-related peptide receptors, is proportional to intracellular levels of cAMP produced (Godinho and Costa, 2003; Chiavegatti et al., 2008). Of more importance, cAMP efflux and subsequent extracellular generation of adenosine elicited by β2-adrenoceptor agonists results in a delayed attenuation of β2-adrenoceptor-induced positive inotropic effect, via activation of A1 ARs (Duarte et al., 2012), as schematically shown in Figure 1B.
The correlation of GsPCR activation, cAMP efflux, and the extracellular cAMP-adenosine pathway has been described in many other cells. For example, the β-adrenoceptor agonist isoproterenol stimulates cAMP secretion from rat cultured glioma cells (Doore et al., 1975) and turkey erythrocytes (Rindler et al., 1978). In mouse adrenocortical tumor cell line, the intracellular cAMP formed in response to ACTH appeared extracellularly in few minutes (Schimmer and Zimmerman, 1976). In healthy volunteers, infusion of glucagon after hepatic venous catheterization was associated with a marked increase in both the splanchnic cAMP production and in the arterial cyclic nucleotide levels (Grill et al., 1979). In addition, while activation of D1 dopamine receptor stimulates cAMP efflux from rat neostriatal cells (Plantie et al., 1983), vasoactive intestinal peptide and cholecystokinin-8 cause a significant increase in cAMP efflux from rat striatal slices (O’Shaughnessy et al., 1987). Many other GsPCR agonists are able to stimulate cAMP efflux, such as corticotropin-releasing hormone and melanocortin (de Koning et al., 1992), vasopressin (Tyagi et al., 1998) and pituitary AC activating polypeptide (Cui et al., 2000). Taking into account that cAMP efflux depends on increased intracellular generation of cyclic nucleotide it is possible to presume that cAMP export could be ubiquitously elicited by activation of every GsPCR.
Conversely, it is also plausible to postulate that by inhibiting Gαi-sensitive ACs and reducing intracellular cAMP generation, receptors linked to Gi protein (GiPCR) would be able to negatively modulate cAMP efflux. For instance, cAMP egress from rat neostriatal slices induced by activation of Gs-linked D-1 dopamine receptors is reduced by agonists of D2 receptor agonists (Stoof and Kebabian, 1981), μ- or δ opioid receptors (Schoffelmeer et al., 1985) and M2 and M4 muscarinic receptors (Schoffelmeer et al., 1988), known to be coupled to Gi-protein. Indeed, several pheromones and fatty acids, components of membrane phospholipids, also inhibit cAMP export (Kanter et al., 1989) by activating free fatty acid receptors, such as FFA5, linked to Gi/o protein (Wang et al., 2006). Thus, inhibition of cAMP egress as consequence of inhibition of cAMP production may provide an additional mechanism by which GiPCR agonists influence the cAMP signaling pathway, as illustrated in Figure 1C. Table 1 presents a list of GPCR receptors linked to Gs and Gi protein (Alexander et al., 2013) that, by modulating intracellular generation of cAMP, may function as regulators of cAMP efflux and extracellular cAMP adenosine pathway.
Table 1
| Gα subunits | ||
|---|---|---|
| Receptors coupled to inhibitory G protein (Gαi) | ||
| Orphans: GPR22, GPR34, GPR37, GPR84,1 MRGPRD, GPR33, GPR37L1, OPN5 | Hydroxycarboxylic acid: HCA1, HCA2, HCA3 | |
| Acetylcholine (Muscarinic): M2, M4 | 5-Hydroxytryptamine: 5-HT1A, 5-HT1B, 5-HT1D–5-HT1F, 5-Ht5A | |
| Adenosine: A1, A3 | Leukotriene/lipoxin/oxoeicosanoids: BLT1–BLT2, FPR2/ALX, OXE | |
| Adrenoceptor (α): α2A, α2B, α2C | Lysophospholipid (LPA): LPA1–LPA4 | |
| Angiotensin: AT2 | Sphingosine 1-phosphate (S1P): S1P1, S1P3–S1P5 | |
| Apelin: HGNC | Melanin-concentrating hormone (MCH): MCH1 | |
| Calcium sensing: CaS | Melatonin: MT1–MT2 | |
| Cannabinoid: CB1, CB2 | Metabotropic glutamate (mGlu): mGlu2–mGlu4; mGlu6–mGlu8 | |
| Chemokine: CCR1–CCR10, CXCR1–CXCR6, CX3CR1, XCR1 | Neuropeptide FF/neuropeptide AF: NPFF2 | |
| Complement peptide: C3a, C5a1 | Neuropeptide W/neuropeptide B: NPBW1–NPBW2 | |
| Dopamine: D2, D3, D4 | Neuropeptide Y: Y1–Y2, Y4–Y6 | |
| Endothelin: ETB | Opioid: δ, κ, μ, NOP | |
| Estrogen (G protein-coupled): GPER | Purinergic P2Y: P2Y12–P2Y13 | |
| Formylpeptide: FPR1, FPR2/ALX | Peptide P518: QRFP | |
| Free fatty acid: FFA3, FFA2, FFA5 | Platelet-activating factor: PAF | |
| Gaba: GabaB | Prostanoid: DP2, EP3 | |
| Galanin: GAL1, GAL2, GAL3 | Proteinase-activated (PARs): PAR1, PAR2, PAR4 | |
| Glycoprotein hormone: TSH, LH | Relaxin family peptide (RXFP): RXFP3–RXFP4 | |
| GPR18 (provisional nomenclature) | Somatostatin (sst): sst1–sst5 | |
| Histamine: H3, H4 | Vasopressin and Oxytocin: OT | |
| Receptors coupled to stimulatory G protein (Gαs) | ||
| Orphans: GPR3-GPR4, GPR6, GPR26, GPR61, GPR65, GPR132, TAAR2, GPR78, GPR174 | Histamine: H2 | |
| 5-Hydroxytryptamine: 5-HT4, 5-HT6–5-HT7 | Lysophospholipid (LPA): LPA3-LPA4 | |
| Adenosine: A2A, A2B | Sphingosine 1-phosphate (S1P): S1P2–S1P4 | |
| Adrenoceptor (β): β1–β3 | Melanocortin: MC1–MC5 | |
| Bile acid | Neuropeptide S: NPS | |
| Calcitonin: CGRP, AM1–AM2, CT, AMY1–AMY3, | Purinergic P2Y: P2Y11 | |
| Cholecystokinin: CCK1, CCK2 | Parathyroid hormone: PTH1–PTH2 | |
| Corticotropin-releasing factor: CRF1, CRF2 | Prostanoid: DP1, EP2, EP4 | |
| Dopamine: D1, D5 | Relaxin family peptide (RXFP): RXFP1–RXFP2 | |
| Endothelin: ETA | Trace Amino: TA1 | |
| Estrogen (G protein-coupled): GPER | Vasopressin and Oxytocin receptors: V2 | |
| Glucagon: glucagon, GLP-1–GLP-2, GIP, GHRH, secretin | Vasoactive intestinal peptide and PACAP: VPAC1, VPAC2, PAC1 | |
| Glycoprotein hormone: FSH, LH | ||
Receptors coupled to stimulatory (Gs) and inhibitory (Gi) G proteins th
Based on Alexander et al. (2013).
Assuming the physiological significance of cAMP efflux and extracellular cAMP-adenosine pathway in modulating GsPCR signaling, impairment of this extracellular feedback mechanism may have profound impact in several physiological processes leading to pathological conditions associated to cardiovascular, muscular and endocrine disorders and/or inflammatory diseases. For example, cAMP secreted from cardiomyocytes attenuates the development of hypertrophy and fibrosis induced by continuous activation of β2-adrenoceptors (Sassi et al., 2014). Similarly, cAMP efflux induced by prolong stimulation of β2-adrenoceptors attenuates skeletal muscle contraction, preserving muscle from deleterious effects of massive Ca2+ release from the sarcoplasmic reticulum (Duarte et al., 2012). In pancreatic acinar cells, cAMP egression through MRP4 clearly attenuates the development of acute pancreatitis induced by caerulein (Ventimiglia et al., 2015). On the other hand, inhibition of cAMP efflux with probenecid reduces bovine sperm capacitation (Osycka-Salut et al., 2014). Finally, the extracellular cAMP-adenosine pathway is able to exert immunoregulatory effects by modulating monocyte function and differentiation through A2A/A2B receptors (Sciaraffia et al., 2014), which is consistent with the marked reduction of ecto-5′-nucleotidases expression in lymphocytes from patients with a variety of immunodeficiency diseases (Resta et al., 1998). Interestingly, certain antioxidants derived from plants such as the flavonoid quercetin, have been found to inhibit cAMP efflux transporters (Pavan et al., 2015), which open new perspectives in the use of natural products as regulators of extracellular cAMP signaling for therapeutic purposes.
cAMP Signaling Microdomains
The compartmentalized expression of cAMP signaling components such as GPCR, AC, PKA, and Epacs (Laflamme and Becker, 1999; Zaccolo, 2009; Terrin et al., 2012) allows the establishment of multiple intracellular cAMP subcompartments. For example, PDEs bind to A kinase-anchoring proteins (AKAPs) forming a PKA-PDE-AKAP complex (Stangherlin and Zaccolo, 2011; Terrin et al., 2012). Likewise, specific AC isoforms have been identified as components of AKAP complexes (Dessauer, 2009), contributing to intracellular compartmentalization of cAMP signaling. In fact, localized expression of ACs generate specific microdomains of elevated concentration of cAMP ensuring signaling specificity, such as those observed in the transverse tubule/junctional sarcoplasmic reticulum network of cardiac and skeletal muscle (Gao et al., 1997; Zaccolo et al., 2002; Menezes-Rodrigues et al., 2013).
Interestingly, the localized expression of MRPs may also play an important role in the intra- and extracellular cAMP signaling process (Cheepala et al., 2013). For example, in the gut epithelia signal compartmentalization of cAMP with MRP4 is essential for cAMP-dependent regulation of chloride channel function (Li et al., 2007). As well, contraction of cardiac myocytes induced by activation of β-adrenoceptor/AC/cAMP cascade can be locally regulated by MRP4 (Sellers et al., 2012). In addition, in vascular smooth muscle cells, MRP4 was found in caveolin-rich membrane fractions regulating cAMP/PKA/CREB pathway cascade (Sassi et al., 2008). Thus, multiprotein signaling complexes, which include MRPs may affect the final GsPCR/cAMP-dependent cellular response. Of more importance, the compartmentalized expression of ARs in caveolae/cholesterol-rich microdomains (Sitaraman et al., 2002; Cordeaux et al., 2008; Garg et al., 2009; Assaife-Lopes et al., 2010) suggests that colocalization of MRP4 and ARs in caveolae microdomains coordinates the cAMP efflux in the vicinity of the AR domain (Xie et al., 2011; D’ Ambrosi and Volonte, 2013).
On the other hand, activation of ARs involved in the extracellular cAMP-adenosine pathway also depends on the availability and distribution of the ecto-enzymes. Ecto-phosphodiesterase and ecto-nucleotidases or adenosine deaminase can very rapidly modulate the extracellular concentrations of adenosine, which will directly affect receptor subtype activation, and as consequence, the final cell response. Interestingly, while all human AR subtypes contain the caveolin binding domain (Mundell and Kelly, 2011), studies analyzing the subcellular distribution of A1 receptors on cardiomyocytes showed that selective activation of A1 receptors with CCPA results in the switch of A1 receptor from caveolin-3-enriched domains to the bulk plasma membrane (Lasley, 2011). The lipid raft localization of A1 receptor seems to be essential for the A1-dependent activation of KATP channels that is involved in cardioprotective effects of adenosine. Disruption of cholesterol-rich microdomains with methyl-cyclodextrin drastically reduces the effect of ARs on rat ventricular myocytes KATP channels (Garg et al., 2009; D’ Ambrosi and Volonte, 2013).
Conclusion
The existence of a system involved in sequential extrusion and extracellular degradation of cAMP definitively extend the intracellular signaling relevance of cAMP to an extracellular level, which allows paracrine and/or autocrine feedback signaling, depending on the AR subtype expressed on the target and neighboring cells. In view of the recognized ability of adenosine to regulate many cellular processes (Burnstock, 2007), the existence of the extracellular cAMP-adenosine reveals new insights into the regulatory mechanisms of cellular response triggered by GsPCR and provides novel therapeutic targets for treatment of a number of diseases associated with dysfunction of GPCR signaling cascade.
Statements
Acknowledgments
We thank Dr. Marcelo Funke and Fernanda Eloi for helpful comments on the manuscript. This work was supported by Fapesp (2011/01519-4; 2012/20148-0) and CNPq to RG, TD, and EP are Ph.D fellow from Capes and CNPq.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AlexanderS. P.BensonH. E.FaccendaE.PawsonA. J.SharmanJ. L.SpeddingM.et al (2013). The Concise guide to PHARMACOLOGY 2013/14: g protein-coupled receptors.Br. J. Pharmacol.1701459–1581. 10.1111/bph.12445
2
AntoniF. A. (2012). New paradigms in cAMP signalling.Mol. Cell. Endocrinol.3533–9. 10.1016/j.mce.2011.10.034
3
AntonioliL.BlandizziC.PacherP.HaskoG. (2013). Immunity, inflammation and cancer: a leading role for adenosine.Nat. Rev. Cancer13842–857. 10.1038/nrc3613
4
Assaife-LopesN.SousaV. C.PereiraD. B.RibeiroJ. A.ChaoM. V.SebastiaoA. M. (2010). Activation of adenosine A2A receptors induces TrkB translocation and increases BDNF-mediated phospho-TrkB localization in lipid rafts: implications for neuromodulation.J. Neurosci.308468–8480. 10.1523/JNEUROSCI.5695-09.2010
5
AzevedoM. F.FauczF. R.BimpakiE.HorvathA.LevyI.de AlexandreR. B.et al (2014). Clinical and molecular genetics of the phosphodiesterases (PDEs).Endocr. Rev.35195–233. 10.1210/er.2013-1053
6
BenderA. T.BeavoJ. A. (2006). Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use.Pharmacol. Rev.58488–520. 10.1124/pr.58.3.5
7
BradleyJ.ReisertJ.FringsS. (2005). Regulation of cyclic nucleotide-gated channels.Curr. Opin. Neurobiol.15343–349. 10.1016/j.conb.2005.05.014
8
BurnstockG. (2007). Purine and pyrimidine receptors.Cell. Mol. Life Sci.641471–1483. 10.1007/s00018-007-6497-0
9
BurnstockG.ArnettT. R.OrrissI. R. (2013). Purinergic signalling in the musculoskeletal system.Purinergic Signal.9541–572. 10.1007/s11302-013-9381-4
10
CheepalaS.HulotJ. S.MorganJ. A.SassiY.ZhangW.NarenA. P.et al (2013). Cyclic nucleotide compartmentalization: contributions of phosphodiesterases and ATP-binding cassette transporters.Annu. Rev. Pharmacol. Toxicol.53231–253. 10.1146/annurev-pharmtox-010611-134609
11
ChenZ. S.LeeK.KruhG. D. (2001). Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine.J. Biol. Chem.27633747–33754. 10.1074/jbc.M104833200
12
ChengD.RenJ.JacksonE. K. (2010). Multidrug resistance protein 4 mediates cAMP efflux from rat preglomerular vascular smooth muscle cells.Clin. Exp. Pharmacol. Physiol.37205–207. 10.1111/j.1440-1681.2009.05272.x
13
ChiavegattiT.CostaV. L.AraujoM. S.GodinhoR. O. (2008). Skeletal muscle expresses the extracellular cyclic AMP-adenosine pathway.Br. J. Pharmacol.1531331–1340. 10.1038/sj.bjp.0707648
14
ColganS. P.EltzschigH. K.EckleT.ThompsonL. F. (2006). Physiological roles for ecto-5′-nucleotidase (CD73).Purinergic Signal.2351–360. 10.1007/s11302-005-5302-5
15
CookW. H.LipkinD.MarkhamR. (1957). The formation of a cyclic dianhydrodiadenylic acid (I) by the alkaline degradation of adenosine-5′-triphosphoric acid (II)1.J. Am. Chem. Soc.793607–3608. 10.1021/ja01570a086
16
CordeauxY.BriddonS. J.AlexanderS. P.KellamB.HillS. J. (2008). Agonist-occupied A3 adenosine receptors exist within heterogeneous complexes in membrane microdomains of individual living cells.FASEB J.22850–860. 10.1096/fj.07-8180com
17
CuiX.LeeS. J.KimS. Z.KimS. H.ChoK. W. (2000). Effects of pituitary adenylate cyclase activating polypeptide27 on cyclic AMP efflux and atrial dynamics in perfused beating atria.Eur. J. Pharmacol.402129–137. 10.1016/S0014-2999(00)00514-8
18
D’ AmbrosiN.VolonteC. (2013). Metabotropic purinergic receptors in lipid membrane microdomains.Curr. Med. Chem.2056–63. 10.2174/0929867311302010007
19
de KoningH. P.JenksB. G.HuchedeB.RoubosE. W. (1992). Dynamics of cyclic-AMP efflux in relation to alpha-MSH secretion from melanotrope cells of Xenopus laevis.Life Sci.511667–1673. 10.1016/0024-3205(92)90311-C
20
DessauerC. W. (2009). Adenylyl cyclase–A-kinase anchoring protein complexes: the next dimension in cAMP signaling.Mol. Pharmacol.76935–941. 10.1124/mol.109.059345
21
DeWireS. M.AhnS.LefkowitzR. J.ShenoyS. K. (2007). Beta-arrestins and cell signaling.Annu. Rev. Physiol.69483–510. 10.1146/annurev.physiol.69.022405.154749
22
DooreB. J.BashorM. M.SpitzerN.MaweR. C.SaierM. H.Jr. (1975). Regulation of adenosine 3′ :5′-monophosphate efflux from rat glioma cells in culture∗.J. Biol. Chem.2504371–4372.
23
DuarteT.Menezes-RodriguesF. S.GodinhoR. O. (2012). Contribution of the extracellular cAMP-adenosine pathway to dual coupling of beta2-adrenoceptors to Gs and Gi proteins in mouse skeletal muscle.J. Pharmacol. Exp. Ther.341820–828. 10.1124/jpet.112.192997
24
DubeyR. K.MiZ.GillespieD. G.JacksonE. K. (1996). Cyclic AMP-adenosine pathway inhibits vascular smooth muscle cell growth.Hypertension28765–771. 10.1161/01.HYP.28.5.765
25
FeoktistovI.GoldsteinA. E.BiaggioniI. (1999). Role of p38 mitogen-activated protein kinase and extracellular signal-regulated protein kinase kinase in adenosine A2B receptor-mediated interleukin-8 production in human mast cells.Mol. Pharmacol.55726–734.
26
FrancisS. H.BlountM. A.CorbinJ. D. (2011). Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions.Physiol. Rev.91651–690. 10.1152/physrev.00030.2010
27
FredholmB. B.IJzermanA. P.JacobsonK. A.LindenJ.MullerC. E. (2011). International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors–an update. Pharmacol. Rev.631–34. 10.1124/pr.110.003285
28
GaoT.PuriT. S.GerhardsteinB. L.ChienA. J.GreenR. D.HoseyM. M. (1997). Identification and subcellular localization of the subunits of L-type calcium channels and adenylyl cyclase in cardiac myocytes.J. Biol. Chem.27219401–19407. 10.1074/jbc.272.31.19401
29
GargV.JiaoJ.HuK. (2009). Regulation of ATP-sensitive K+ channels by caveolin-enriched microdomains in cardiac myocytes.Cardiovasc. Res.8251–58. 10.1093/cvr/cvp039
30
GironM. C.BinA.BrunP.EtteriS.BolegoC.FlorioC.et al (2008). Cyclic AMP in rat ileum: evidence for the presence of an extracellular cyclic AMP-adenosine pathway.Gastroenterology1341116–1126. 10.1053/j.gastro.2008.01.030
31
GloerichM.BosJ. L. (2010). Epac: defining a new mechanism for cAMP action.Annu. Rev. Pharmacol. Toxicol.50355–375. 10.1146/annurev.pharmtox.010909.105714
32
GodinhoR. O.CostaV. L.Jr. (2003). Regulation of intracellular cyclic AMP in skeletal muscle cells involves the efflux of cyclic nucleotide to the extracellular compartment.Br. J. Pharmacol.138995–1003. 10.1038/sj.bjp.0705130
33
GrillV.CerasiE.WahrenJ. (1979). Role of cyclic AMP in glucagon-induced stimulation of hepatic glucose output in man.Scand. J. Clin. Lab. Invest.39689–696. 10.3109/00365517909108159
34
GuoY.KotovaE.ChenZ. S.LeeK.Hopper-BorgeE.BelinskyM. G.et al (2003). MRP8 ATP-binding cassette C11 (ABCC11), Is a cyclic nucleotide efflux pump and a resistance factor for Fluoropyrimidines 2′,3′-Dideoxycytidine and 9′-(2′-Phosphonylmethoxyethyl)adenine.J. Biol. Chem.27829509–29514. 10.1074/jbc.M304059200
35
HaraY.SassiY.GuibertC.GambaryanN.DorfmullerP.EddahibiS.et al (2011). Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice.J. Clin. Invest.1212888–2897. 10.1172/JCI45023
36
HeadrickJ. P.AshtonK. J.Rose’meyerR. B.PeartJ. N. (2013). Cardiovascular adenosine receptors: expression, actions and interactions.Pharmacol. Ther.14092–111. 10.1016/j.pharmthera.2013.06.002
37
IdzkoM.FerrariD.EltzschigH. K. (2014a). Nucleotide signalling during inflammation.Nature509310–317. 10.1038/nature13085
38
IdzkoM.FerrariD.RiegelA. K.EltzschigH. K. (2014b). Extracellular nucleotide and nucleoside signaling in vascular and blood disease.Blood1241029–1037. 10.1182/blood-2013-09-402560
39
ImuraH.MatsukuraS.MatsuyamaH.SetsudaT.MiyakeT. (1965). Adrenal steroidogenic effect of adenosine 3′,5′-monophosphate and its derivatives in vivo.Endocrinology76933–937. 10.1210/endo-76-5-933
40
JacksonE. K.MiZ.GillespieD. G.DubeyR. K. (1997). Metabolism of cAMP to adenosine in the renal vasculature.J. Pharmacol. Exp. Ther.283177–182.
41
JacksonE. K.RaghvendraD. K. (2004). The extracellular cyclic AMP-adenosine pathway in renal physiology.Ann. Rev. Physiol.66571–599. 10.1146/annurev.physiol.66.032102.111604
42
JedlitschkyG.BurchellB.KepplerD. (2000). The Multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides.J. Biol. Chem.27530069–30074. 10.1074/jbc.M005463200
43
JedlitschkyG.TirschmannK.LubenowL. E.NieuwenhuisH. K.AkkermanJ. W.GreinacherA.et al (2004). The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage.Blood1043603–3610. 10.1182/blood-2003-12-4330
44
KanterJ. R.HageyL. R.BruntonL. L. (1989). Inhibition of cyclic AMP efflux by insect pheromones and fatty acids.FEBS Lett.244149–153. 10.1016/0014-5793(89)81181-0
45
KruhG. D.BelinskyM. G. (2003). The MRP family of drug efflux pumps.Oncogene227537–7552. 10.1038/sj.onc.1206953
46
LaflammeM. A.BeckerP. L. (1999). G(s) and adenylyl cyclase in transverse tubules of heart: implications for cAMP-dependent signaling.Am. J. Physiol.277H1841–H1848.
47
LarssonH. P. (2010). How is the heart rate regulated in the sinoatrial node? Another piece to the puzzle.J. Gen. Physiol.136237–241. 10.1085/jgp.201010506
48
LasleyR. D. (2011). Adenosine receptors and membrane microdomains.Biochim. Biophys. Acta18081284–1289. 10.1016/j.bbamem.2010.09.019
49
LevineR. A.VogelJ. A. (1966). Cardiovascular and metabolic effects of cyclic adenosine 3′, 5′-monophosphate in unanesthetized dogs.J. Pharmacol. Exp. Ther.151262–272.
50
LiC.KrishnamurthyP. C.PenmatsaH.MarrsK. L.WangX. Q.ZaccoloM.et al (2007). Spatiotemporal coupling of cAMP transporter to CFTR chloride channel function in the gut epithelia.Cell131940–951. 10.1016/j.cell.2007.09.037
51
Menezes-RodriguesF. S.Pires-OliveiraM.DuarteT.Paredes-GameroE. J.ChiavegattiT.GodinhoR. O. (2013). Calcium influx through L-type channels attenuates skeletal muscle contraction via inhibition of adenylyl cyclases.Eur. J. Pharmacol.720326–334. 10.1016/j.ejphar.2013.10.009
52
MiZ.JacksonE. K. (1998). Evidence for an endogenous cAMP-adenosine pathway in the rat kidney.J. Pharmacol. Exp. Ther.287926–930.
53
MoreiraI. S. (2014). Structural features of the G-protein/GPCR interactions.Biochim. Biophys. Acta184016–33. 10.1016/j.bbagen.2013.08.027
54
MullerC. E.JacobsonK. A. (2011). Recent developments in adenosine receptor ligands and their potential as novel drugs.Biochim. Biophys. Acta18081290–1308. 10.1016/j.bbamem.2010.12.017
55
MundellS.KellyE. (2011). Adenosine receptor desensitization and trafficking.Biochim. Biophys. Acta18081319–1328. 10.1016/j.bbamem.2010.06.007
56
O’ShaughnessyC.PoatJ. A.TurnbullM. J. (1987). Cyclic AMP efflux from rat striatal slices is enhanced by CCK.Biochem. Pharmacol.36976–979. 10.1016/0006-2952(87)90196-1
57
Osycka-SalutC.DiezF.BurdetJ.GervasiM. G.FranchiA.BianciottiL. G.et al (2014). Cyclic AMP efflux, via MRPs and A1 adenosine receptors, is critical for bovine sperm capacitation.Mol. Hum. Reprod.2089–99. 10.1093/molehr/gat053
58
PavanB.CapuzzoA.ForlaniG. (2015). Quercetin and quercetin-3-O-glucoside interact with different components of the cAMP signaling cascade in human retinal pigment epithelial cells.Life Sci.121166–173. 10.1016/j.lfs.2014.11.010
59
PierceK. L.PremontR. T.LefkowitzR. J. (2002). Signalling: seven-transmembrane receptors.Nat. Rev. Mol. Cell. Biol.3639–650. 10.1038/nrm908
60
PlantieJ. F.MulderA. H.StoofJ. C. (1983). 3-PPP antagonizes the in vitro effects of D-1 and D-2 dopamine receptor agonists in rat neostriatum.Eur. J. Pharmacol.91317–320. 10.1016/0014-2999(83)90486-7
61
RallT. W.SutherlandE. W.BerthetJ. (1957). The relationship of epinephrine and glucagon to liver phosphorylase: IV. Effect of epinephrine and glucagon on the reactivation of phosphorylase in liver homogenates. J. Biol. Chem.224463–475.
62
RasmussenH.PechetM.FastD. (1968). Effect of dibutyryl cyclic adenosine 3′,5′-monophosphate, theophylline, and other nucleotides upon calcium and phosphate metabolism.J. Clin. Invest.471843–1850. 10.1172/JCI105874
63
RestaR.YamashitaY.ThompsonL. F. (1998). Ecto-enzyme and signaling functions of lymphocyte CD73.Immunol. Rev.16195–109. 10.1111/j.1600-065X.1998.tb01574.x
64
RibeiroJ. A.SebastiaoA. M.and deMendonaA. (2002). Adenosine receptors in the nervous system: pathophysiological implications.Prog. Neurobiol.68377–392. 10.1016/S0301-0082(02)00155-7
65
RindlerM. J.BashorM. M.SpitzerN.SaierM. H.Jr. (1978). Regulation of adenosine 3′:5′-monophosphate efflux from animal cells.J. Biol. Chem.2535431–5436.
66
RobisonG. A.ButcherR. W.OyeI.MorganH. E.and sutherlandE. W. (1965). The effect of epinephrine on adenosine 3′, 5′-phosphate levels in the isolated perfused rat heart.Mol. Pharmacol.1168–177.
67
SadanaR.DessauerC. W. (2009). Physiological roles for G protein-regulated adenylyl cyclase isoforms: insights from knockout and overexpression studies.Neurosignals175–22. 10.1159/000166277
68
SagerG.RavnaA. W. (2009). Cellular efflux of cAMP and cGMP-a question about selectivity.Mini Rev. Med. Chem.91009–1013. 10.2174/138955709788681654
69
SassiY.Abi-GergesA.FauconnierJ.MougenotN.ReikenS.HaghighiK.et al (2011). Regulation of cAMP homeostasis by the efflux protein MRP4 in cardiac myocytes.FASEB J.261009–1017. 10.1096/fj.11-194027
70
SassiY.AhlesA.TruongD. J. J.BaqiY.LeeS. Y.HusseB.et al (2014). Cardiac myocyte-secreted cAMP exerts paracrine action via adenosine receptor activation.J. Clin. Invest.1245385–5397. 10.1172/JCI74349
71
SassiY.LipskaiaL.VandecasteeleG.NikolaevV. O.HatemS. N.CohenA. F.et al (2008). Multidrug resistance-associated protein 4 regulates cAMP-dependent signaling pathways and controls human and rat SMC proliferation.J. Clin. Invest.1182747–2757. 10.1172/JCI35067
72
SchimmerB. P.ZimmermanA. E. (1976). Steroidogenesis and extracellular cAMP accumulation in adrenal tumor cell cultures.Mol. Cell. Endocrinol.4263–270. 10.1016/0303-7207(76)90060-5
73
SchoffelmeerA. N.HansenH. A.StoofJ. C.MulderA. H. (1985). Inhibition of dopamine-stimulated cyclic AMP efflux from rat neostriatal slices by activation of mu- and delta-opioid receptors: a permissive role for D-2 dopamine receptors.Eur. J. Pharmacol.118363–366. 10.1016/0014-2999(85)90150-5
74
SchoffelmeerA. N.HogenboomF.MulderA. H. (1988). M-1 and M-2 muscarinic receptor-mediated inhibition of dopamine-sensitive adenylate cyclase in rat neostriatum: a permissive role for D-2 dopamine receptors.J. Pharmacol. Exp. Ther.245658–663.
75
SchulteG.FredholmB. B. (2003). Signalling from adenosine receptors to mitogen-activated protein kinases.Cell. Signal.15813–827. 10.1016/S0898-6568(03)00058-5
76
SciaraffiaE.RiccomiA.LindstedtR.GesaV.CirelliE.PatrizioM.et al (2014). Human monocytes respond to extracellular cAMP through A2A and A2B adenosine receptors.J. Biol.96113–122. 10.1189/jlb.3A0513-302RR
77
SellersZ. M.NarenA. P.XiangY.BestP. M. (2012). MRP4 and CFTR in the regulation of cAMP and β-adrenergic contraction in cardiac myocytes Eur.J. Pharmacol.68180–87. 10.1016/j.ejphar.2012.02.018
78
ShethS.BritoR.MukherjeaD.RybakL. P.RamkumarV. (2014). Adenosine receptors: expression, function and regulation.Int. J. Mol. Sci.152024–2052. 10.3390/ijms15022024
79
SitaramanS. V.WangL.WongM.BruewerM.HobertM.YunC. H.et al (2002). The adenosine 2b receptor is recruited to the plasma membrane and associates with E3KARP and Ezrin upon agonist stimulation.J. Biol. Chem.27733188–33195. 10.1074/jbc.M202522200
80
SmoakeJ. A.McMahonK. L.WrightR. K.SolomonS. S. (1981). Hormonally sensitive cyclic AMP phosphodiesterase in liver cells. An ecto-enzyme. J. Biol. Chem.2568531–8535.
81
StangherlinA.ZaccoloM. (2011). Local termination of 3′-5′-cyclic adenosine monophosphate signals: the role of A kinase anchoring protein-tethered phosphodiesterases.J. Cardiovasc. Pharmacol.58345–353. 10.1097/FJC.0b013e3182214f2b
82
StoofJ. C.KebabianJ. W. (1981). Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum.Nature294366–368. 10.1038/294366a0
83
StrouchM. B.JacksonE. K.MiZ.MetesN. A.CareyG. B. (2005). Extracellular cyclic AMP-adenosine pathway in isolated adipocytes and adipose tissue.Obes. Res.13974–981. 10.1038/oby.2005.114
84
TerrinA.MonterisiS.StangherlinA.ZoccaratoA.KoschinskiA.SurdoN. C.et al (2012). PKA and PDE4D3 anchoring to AKAP9 provides distinct regulation of cAMP signals at the centrosome.J. Cell. Biol.198607–621. 10.1083/jcb.201201059
85
TrincavelliM. L.DanieleS.MartiniC. (2010). Adenosine receptors: what we know and what we are learning.Curr. Top. Med. Chem.10860–877. 10.2174/156802610791268756
86
TyagiM. G.HandaR. K.StephenP. M.BapnaJ. S. (1998). Vasopressin induces dopamine release and cyclic AMP efflux from the brain of water-deprived rats: inhibitory effect of vasopressin V2 receptor-mediated phosphorylation.Biol. Signals Recept.7328–336. 10.1159/000014556
87
VallonV.MuhlbauerB.OsswaldH. (2006). Adenosine and kidney function.Physiol. Rev.86901–940. 10.1152/physrev.00031.2005
88
VentimigliaM. S.NajensonA. C.PerazzoJ. C.CarozzoA.VattaM. S.DavioC. A.et al (2015). Blockade of multidrug resistance associated proteins aggravates acute pancreatitis and blunts atrial natriuretic factor benefitial effect in rats: role of MRP4/ABCC4.Mol. Med.10.2119/molmed.2014.00166[Epub ahead of print].
89
VerrierJ. D.ExoJ. L.JacksonT. C.RenJ.GillespieD. G.DubeyR. K.et al (2011). Expression of the 2′,3′-cAMP-adenosine pathway in astrocytes and microglia.J. Neurochem.118979–987. 10.1111/j.1471-4159.2011.07392.x
90
WalshD. A.PerkinsJ. P.KrebsE. G. (1968). An adenosine 3′,5′-monophosphate-dependant protein kinase from rabbit skeletal muscle.J. Biol. Chem.2433763–3765.
91
WangJ.WuX.SimonaviciusN.TianH.LingL. (2006). Medium-chain fatty acids as ligands for orphan G protein-coupled receptor GPR84.J. Biol. Chem.28134457–34464. 10.1074/jbc.M608019200
92
WeiC. J.LiW.ChenJ. F. (2011). Normal and abnormal functions of adenosine receptors in the central nervous system revealed by genetic knockout studies.Biochim. Biophys. Acta18081358–1379. 10.1016/j.bbamem.2010.12.018
93
WooY. T.ManeryJ. F. (1973). Cyclic AMP phosphodiesterase activity at the external surface of intact skeletal muscles and stimulation of the enzyme by insulin.Arch. Biochem. Biophys.154510–519. 10.1016/0003-9861(73)90003-9
94
XieM.RichT. C.ScheitrumC.ContiM.RichterW. (2011). Inactivation of multidrug resistance proteins disrupts both cellular extrusion and intracellular degradation of cAMP.Mol. Pharmacol.80281–293. 10.1124/mol.111.071134
95
ZaccoloM. (2009). cAMP signal transduction in the heart: understanding spatial control for the development of novel therapeutic strategies.Br.J. Pharmacol.15850–60. 10.1111/j.1476-5381.2009.00185.x
96
ZaccoloM.MagalhaesP.PozzanT. (2002). Compartmentalisation of cAMP and Ca(2+) signals.Curr. Opin. Cell. Biol.14160–166. 10.1016/S0955-0674(02)00316-2
97
ZimmermannH.ZebischM.StraterN. (2012). Cellular function and molecular structure of ecto-nucleotidases.Purinergic Signal.8437–502. 10.1007/s11302-012-9309-4
Summary
Keywords
G protein-coupled receptors, cyclic AMP, cAMP efflux, adenosine, adenosine receptors, ABC transporters, ecto-phosphodiesterase, ecto-5′-nucleotidase
Citation
Godinho RO, Duarte T and Pacini ESA (2015) New perspectives in signaling mediated by receptors coupled to stimulatory G protein: the emerging significance of cAMP efflux and extracellular cAMP-adenosine pathway. Front. Pharmacol. 6:58. doi: 10.3389/fphar.2015.00058
Received
07 January 2015
Accepted
06 March 2015
Published
25 March 2015
Volume
6 - 2015
Edited by
Claudio M. Costa-Neto, University of Sao Paulo, Brazil
Reviewed by
Antonio Macchiarulo, University of Perugia, Italy; Lauren Therese May, Monash University, Australia
Copyright
© 2015 Godinho, Duarte and Pacini.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Rosely O. Godinho, Disciplina Farmacologia Celular, Departamento de Farmacologia, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Três de Maio 100, 3rd Floor, Vila Clementino, São Paulo, SP 04044-020, Brazil godinho@unifesp.br
Specialty section: This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.